Peptide Advocate
Back to News

/ Peptide Advocate

Important Read!
Not FDA-Approved8/10 · Recommended

Retatrutide: What It Is and How It Works

Retatrutide is not FDA-approved. It is an investigational drug currently in Phase 3 clinical trials. This article summarizes published research for educational purposes — it is not medical advice, and it is not an endorsement of using retatrutide outside of a clinical trial.

Retatrutide: what it is and how it works in your body

One weekly injection, three hormone signals, and the largest weight-loss and liver-fat results reported for any incretin drug so far. It's also still an experimental medicine. Here's what the research actually shows, in plain language.

Peptide Advocate · Evidence review · Updated September 2026

What it isAn investigational peptide that activates three metabolic hormone receptors at once — GLP-1, GIP, and glucagon3
StatusIn Phase 3 clinical trials (the TRIUMPH program). Not FDA-approved. No brand name yet
How it's takenA small injection under the skin, once a week, in ongoing trials
Headline resultUp to 28.3% average weight loss at the top dose in an 80-week trial7

What is retatrutide?

Retatrutide (development code LY3437943) is an experimental peptide made by Eli Lilly — the same company behind tirzepatide (Mounjaro, Zepbound). It belongs to the same drug family, called incretin receptor agonists, but goes a step further. Where semaglutide (Ozempic, Wegovy) activates one hormone receptor and tirzepatide activates two, retatrutide is a triple agonist: a single 26-amino-acid peptide engineered to activate three receptors at once.3 A fatty-acid tail attached to the chain extends its half-life to roughly six days, the same trick that lets tirzepatide and semaglutide work from a once-weekly shot.

As of September 2026, retatrutide has not been approved by the FDA, EMA, MHRA, or any other regulator, and it cannot be legally prescribed outside of a clinical trial. Eli Lilly's Phase 3 program, called TRIUMPH, has reported several positive trials since December 2025, and the company has indicated it plans to submit for FDA approval around late 2026 or early 2027.

How it works: one molecule, three receptors

When you eat, your gut releases hormones called incretins — mainly GIP and GLP-1 — that tell your pancreas to release insulin and help your brain register that you've eaten. A third hormone, glucagon, normally works the opposite way, raising blood sugar between meals. Retatrutide is engineered to activate the receptors for all three at once, which is unusual: no other approved or investigational obesity drug currently does this.3

One molecule, three receptors Retatrutide binds the GLP-1, GIP, and glucagon receptors on the surface of cells, each producing a different metabolic effect. Retatrutide one peptide chain + a fatty-acid tail that makes it last a week Outside the cell Inside the cell GLP-1 receptor GIP receptor Glucagon receptor Slows how fast the stomach empties, curbs appetite Boosts insulin sensitivity, improves fat cell handling Raises resting energy burn, mobilizes stored liver fat No other approved or investigational obesity drug currently activates all three receptors at once.
Retatrutide acts on three different receptors on the surface of cells. Diagram: Peptide Advocate.
Because retatrutide activates three receptors instead of one or two, researchers call it a “triple agonist.” It's the same drug family as semaglutide (one receptor) and tirzepatide (two receptors), just with an added target — and, in trials so far, bigger effects.

A tour of the body

GLP-1, GIP, and glucagon receptors sit in tissues throughout the body, so retatrutide's effects show up in many places beyond appetite. The colored dots below show which receptor pathway is thought to drive each effect.

Where retatrutide acts in the body A grid summarizing retatrutide's effects on the brain, stomach, pancreas, liver, fat tissue, heart and vessels, kidneys, and muscle, based on clinical trial data. Eight body systems, one drug Based on Phase 2 and Phase 3 (TRIUMPH) clinical trial data through 2026 Brain Reduced hunger signals, earlier fullness Stomach Slower gastric emptying; common source of nausea Pancreas Glucose-dependent insulin release, better A1c Liver Up to 82–86% liver fat reduction in trials Fat tissue Higher energy expenditure, fat breakdown Heart & vessels Lower blood pressure, better lipids; heart rate up Kidneys Reduced urine albumin in early trial data Muscle & bone Some lean mass loss with rapid weight loss
Diagram: Peptide Advocate. See sources below for individual trial citations.

Brain and appetite

GLP-1 receptors in the hindbrain and GIP receptors in the hypothalamus work together to reduce hunger signaling and increase satiety. Researchers believe GIP activity may also help blunt the nausea that GLP-1 activation alone tends to cause.

Digestive system

Slower gastric emptying is part of why the drug works — it keeps people feeling full longer — but it's also the source of the most common side effects: nausea, vomiting, diarrhea, and constipation, especially during dose increases.

Pancreas and blood sugar

Both GLP-1 and GIP stimulate insulin secretion in a glucose-dependent way. In a Phase 2 trial in people with type 2 diabetes, HbA1c improved by an average of 2.2 percentage points, with 82% of participants reaching an HbA1c of 6.5% or lower after 36 weeks.1

Liver

This is where retatrutide's results have been especially striking. In a Phase 2a trial focused on liver fat, participants on the 12 mg dose saw liver fat drop by an average of 82.4% at 24 weeks, and 86% of them reached a normal liver fat level.2 A dedicated Phase 3 trial for MASLD (metabolic dysfunction-associated steatotic liver disease) is underway.

Fat tissue and energy expenditure

The glucagon receptor component increases resting energy expenditure — the body burns more calories at rest — on top of reduced calorie intake from appetite suppression. This dual mechanism is what researchers point to when explaining retatrutide's edge over single- and dual-receptor drugs on weight loss so far.

Heart and blood vessels

Across TRIUMPH, retatrutide has consistently improved cardiovascular risk markers: in TRIUMPH-4, the 12 mg dose lowered systolic blood pressure by 14.0 mmHg, alongside lower non-HDL cholesterol, triglycerides, and inflammation markers.4 One trade-off is a modest heart-rate increase. A dedicated cardiovascular outcomes trial is running separately to see whether marker improvements translate into fewer heart attacks and strokes.

Kidneys

Early data is encouraging but preliminary: post-hoc analyses show the 12 mg dose reduced urine albumin-to-creatinine ratio by roughly 31–37%. This hasn't been the focus of a dedicated trial yet.

Muscle and bone

As with other drugs in this class, rapid weight loss brings a real risk of losing lean muscle mass along with fat. Trial data suggests the proportion lost is roughly comparable to lifestyle-based weight loss — adequate protein intake and resistance training are the usual recommended countermeasures.

Liver fat: the standout result

Retatrutide's liver fat data is the most striking result reported for any drug in this class. In the Phase 2a substudy, liver fat reduction scaled clearly with dose:

Liver fat, dose by dose Relative change in liver fat at 24 weeks by dose: placebo +0.3%, 1mg -42.9%, 4mg -57.0%, 8mg -81.4%, 12mg -82.4%. Liver fat, dose by dose Relative change in liver fat at 24 weeks, Phase 2a substudy (Sanyal et al., Nature Medicine, 2024) 0% −20% −40% −60% −80% +0.3% −42.9% −57.0% −81.4% −82.4% Placebo 1 mg 4 mg 8 mg 12 mg 86% of participants on the 12 mg dose reached a normal liver fat level (under 5%) by week 48.
Liver fat reduction scaled clearly with dose in the Phase 2a substudy.2

A dedicated Phase 3 trial for MASLD is underway, with results expected later in 2026.

What the trials show

TrialPopulationKey result
Phase 2Obesity, no diabetes; 48 weeksUp to 24.2% weight loss at 12 mg1
Phase 2a MASLD substudyObesity with elevated liver fat; 24 weeksUp to 82.4% liver fat reduction2
TRIUMPH-4Obesity/overweight + knee osteoarthritis; 68 weeks28.7% weight loss; 75.8% less knee pain4
TRIUMPH-1General obesity, 2,339 adults; 80 weeks28.3% weight loss at 12 mg vs. 2.2% placebo7
TRANSCEND-T2D-1Type 2 diabetes; 40 weeks16.8% weight loss6

Individual results vary, and weight loss and metabolic improvements scale with dose. As with any drug in this class, weight regain after stopping treatment is anticipated based on the mechanism, though this hasn't been fully characterized for retatrutide specifically since it's still in trials.

Side effects and safety

Common side effects

The side effects reported so far are broadly similar to other incretin-based drugs. Most common: nausea (roughly 40–50% of participants), diarrhea, constipation, and vomiting — mainly during dose escalation, generally mild-to-moderate, and tending to improve over time. Discontinuation due to side effects in TRIUMPH-1 was 2.2% at 4 mg, 4.5% at 9 mg, and 5.1% at 12 mg, versus 0% on placebo.7

Two differences from GLP-1-only drugs stand out: a modest, dose-dependent heart-rate increase (roughly 5–10 bpm), attributed to the glucagon receptor component; and dysesthesia, an unusual tingling or “pins and needles” skin sensation reported at higher doses in Phase 3 trials.

What we don't know yet

  • It isn't approved for any use. Retatrutide has not been reviewed or approved by the FDA, EMA, MHRA, or any other regulator. There is no legitimate branded or generic version — the only way to legally receive it is enrollment in a clinical trial.
  • Long-term safety isn't established. Trials to date run well under two years. Rare or long-term risks — the kind that show up after a drug reaches millions of people — simply can't be known yet.
  • Serious risks common to this drug class — pancreatitis, gallbladder problems, thyroid C-cell tumors in animal studies — are being monitored in retatrutide's trials but haven't been separately quantified for it.
  • “Research use only” or gray-market versions sold online carry no guarantee of identity, purity, sterility, or dose, and are not a legitimate way to access this drug. We don't recommend them.

Where things stand

Eli Lilly's TRIUMPH program has enrolled more than 5,800 participants across trials in obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, cardiovascular disease, and liver disease.6 Until an approval decision is made, retatrutide remains available only to people enrolled in clinical trials.

Key dates

  1. 2023 · Phase 2 obesity results published in NEJM1
  2. 2024 · Phase 2a MASLD substudy published in Nature Medicine2
  3. December 2025 · TRIUMPH-4 topline results reported4
  4. March 2026 · TRANSCEND-T2D-1 (type 2 diabetes) results reported6
  5. May 2026 · TRIUMPH-1 (general obesity) results reported7
  6. Late 2026 / early 2027 (estimated) · Planned FDA submission

The bottom line

Retatrutide is the most metabolically active investigational obesity drug studied to date. By activating three hormone receptors instead of one or two, it has produced the largest weight loss and liver fat reductions reported for any incretin-based compound so far. But it is still investigational: not FDA-approved, not legally available outside clinical trials, and without an established long-term safety record. For now, the only legitimate way to access it is through enrollment in an ongoing trial.

References

  1. Jastreboff AM, et al. Triple–hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023.
  2. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. nature.com/articles/s41591-024-03018-2
  3. Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist. Cell Metabolism. 2022.
  4. Eli Lilly and Company. Investor press release on TRIUMPH-4 topline results. December 2025. investor.lilly.com
  5. Triple agonism based therapies for obesity. PMC, National Library of Medicine. ncbi.nlm.nih.gov/pmc/articles/PMC12304053
  6. Retatrutide. Wikipedia. en.wikipedia.org/wiki/Retatrutide
  7. Lilly's retatrutide displays positive topline results in successful Phase III trial. PharmExec. 2026.

This article is for general education and is not medical advice. Retatrutide is investigational and not approved for any use; it is not legally available outside clinical trials. Information is current as of September 2026 and may change as new research and regulatory decisions are published. Diagrams are original illustrations by Peptide Advocate.

Peptides Referenced

Retatrutide

GLP-1 / GIP / Glucagon Agonist

Triple agonist targeting GLP-1, GIP, and glucagon receptors for next-generation weight loss and metabolic support.